MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
出版年份 2015 全文链接
标题
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
作者
关键词
-
出版物
Cell Death & Disease
Volume 6, Issue 1, Pages e1593-e1593
出版商
Springer Nature
发表日期
2015-01-16
DOI
10.1038/cddis.2014.525
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
- (2014) Bart Vanhaesebroeck et al. CANCER CELL
- Targeting mTORC1-Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells
- (2014) A. Sharma et al. MOLECULAR CANCER RESEARCH
- Kinase inhibitors overachieve in CLL
- (2014) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways
- (2013) Juraj Bodo et al. BRITISH JOURNAL OF HAEMATOLOGY
- ABT-199: Taking Dead Aim at BCL-2
- (2013) Matthew S. Davids et al. CANCER CELL
- Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
- (2013) François Vaillant et al. CANCER CELL
- GAPDH binds to active Akt, leading to Bcl-xL increase and escape from caspase-independent cell death
- (2013) M A Jacquin et al. CELL DEATH AND DIFFERENTIATION
- Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
- (2013) Giulia Fabbri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
- (2013) F. Abulwerdi et al. MOLECULAR CANCER THERAPEUTICS
- BH3 Mimetics: Status of the Field and New Developments
- (2013) C. Billard MOLECULAR CANCER THERAPEUTICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Evading apoptosis in cancer
- (2013) Kaleigh Fernald et al. TRENDS IN CELL BIOLOGY
- BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
- (2013) A Sharma et al. Cell Death & Disease
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
- (2012) M. S. Davids et al. BLOOD
- Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1
- (2012) Chuanbing Zang et al. CANCER LETTERS
- Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism
- (2012) M. Rahmani et al. CANCER RESEARCH
- Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells
- (2012) S. Mazumder et al. CANCER RESEARCH
- Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation
- (2012) Kenichiro Doi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Delving deeper: MCL-1's contributions to normal and cancer biology
- (2012) Rhonda M. Perciavalle et al. TRENDS IN CELL BIOLOGY
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
- (2011) S. Al-harbi et al. BLOOD
- Akt-Dependent Glucose Metabolism Promotes Mcl-1 Synthesis to Maintain Cell Survival and Resistance to Bcl-2 Inhibition
- (2011) J. L. Coloff et al. CANCER RESEARCH
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
- (2011) A M Martelli et al. LEUKEMIA
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- Mcl-1; the molecular regulation of protein function
- (2010) Luke W. Thomas et al. FEBS LETTERS
- The BCL-2 Family Reunion
- (2010) Jerry E. Chipuk et al. MOLECULAR CELL
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started